fv-100 fv-100 fv-100, also known as cf1743, is an orally available nucleoside analogue drug with antiviral activity. it may be effective against shingles. fv-100 names iupac name 3-(2-deoxy-β-d-erythro-pentofuranosyl)-6-(4-pentylphenyl)furopyrimidin-2(3h)-one systematic iupac name 3--6-(4-pentylphenyl)furopyrimidin-2(3h)-one other names cf1743 identifiers cas number 956483-02-6 y 3d model (jsmol) interactive image pubchem cid 493485 unii 0nj5f6d4u7 y comptox dashboard (epa) dtxsid60185781 smiles cccccc1=cc=c(c=c1)c2=cc3=cn(c(=o)n=c3o2)4c((o4)co)o properties chemical formula c22h26n2o5 molar mass 398.459 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references it was discovered in 1999 in the laboratories of prof chris mcguigan, welsh school of pharmacy and prof. jan balzarini, rega institute, leuven, belgium. clinical trials fv-100 was tested against valaciclovir in a phase ii trial in patients with herpes zoster. the trial was sponsored by bristol-myers squibb. the drug is currently being developed by contravir pharmaceuticals, inc., edison, new jersey. it has reached phase iii clinical trials.